newsfilter
← Latest News
Business Wire·

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's